Diaceutics PLC (FRA:7DC) Stock Price, Trades & News

Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	6.38
Equity-to-Asset	0.81
Debt-to-Equity	0.03
Debt-to-EBITDA	0.19
Interest Coverage	0.74
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	10.24	Distress Grey Safe
Beneish M-Score	-2.23	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	25.8
	3-Year EBITDA Growth Rate	19.3
	3-Year EPS without NRI Growth Rate	-50
	3-Year Book Growth Rate	-1.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	358.82
	Future 3-5Y Total Revenue Growth Rate Estimate	20.4

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	63.39
	9-Day RSI	51.76
	14-Day RSI	46.56
	3-1 Month Momentum %	-8.67
	6-1 Month Momentum %	11.27
	12-1 Month Momentum %	23.44

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.43
	Quick Ratio	3.43
	Cash Ratio	0.86
	Days Sales Outstanding	86.77
	Days Payable	66.92

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.2
	Shareholder Yield %	-0.04

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	81.9
	Operating Margin %	0.11
	Net Margin %	0.25
	EBITDA Margin %	16.06
	FCF Margin %	-13.72
	OCF Margin %	3.08
	ROE %	0.25
	ROA %	0.2
	ROIC %	0.04
	3-Year ROIIC %	-4.18
	ROC (Joel Greenblatt) %	6.45
	ROCE %	0.9
	Years of Profitability over Past 10-Year	8

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	739.01
	Forward PE Ratio	231.43
	PE Ratio without NRI	739.01
	Shiller PE Ratio	435.97
	PEG Ratio	10.92
	PS Ratio	3.28
	PB Ratio	3.09
	Price-to-Tangible-Book	5.13
	Price-to-Operating-Cash-Flow	105.58
	EV-to-EBIT	326.02
	EV-to-Forward-EBIT	24.33
	EV-to-EBITDA	19.02
	EV-to-Forward-EBITDA	12.12
	EV-to-Revenue	3.05
	EV-to-Forward-Revenue	2.45
	EV-to-FCF	-22.28
	Price-to-GF-Value	0.77
	Price-to-Peter-Lynch-Fair-Value	54.67
	Price-to-Graham-Number	13.67
	Price-to-Net-Current-Asset-Value	6.31
	Earnings Yield (Greenblatt) %	0.31
	FCF Yield %	-4.26
	Forward Rate of Return (Yacktman) %	16.75

Financials (Next Earnings Date:2026-09-23 Est.)

Annual Quarterly TTM

FRA:7DC's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Diaceutics PLC Executives

Details

GF Value™: €2.13

FRA:7DC

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Medium warning sign with 7DC. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	44.426
	EPS (TTM) (€)	0.001
	Beta	1.6661
	3-Year Sharpe Ratio	0.61
	3-Year Sortino Ratio	1.09
	Volatility %	59.3
	14-Day RSI	46.56
	14-Day ATR (€)	0.028529
	20-Day SMA (€)	1.611
	12-1 Month Momentum %	23.44
	52-Week Range (€)	1.24 - 2.02
	Shares Outstanding (Mil)	84.63

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Diaceutics PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Diaceutics PLC Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings conference call for 2026	2026-09-23 09:30	In 84 days
Second quarter earnings results for 2026	2026-09-23	In 83 days
General meeting for 2026	2026-06-25 09:30	1.62 (+0.00%)
Annual report for 2025	2026-05-29	1.57 (-4.85%)
Fourth quarter earnings conference call for 2025	2026-05-26 09:00	1.86 (+0.00%)
Fourth quarter earnings results for 2025	2026-05-26	1.86 (+0.00%)
Second quarter earnings conference call for 2025	2025-09-23 09:30	1.68 (+2.44%)
Second quarter earnings results for 2025	2025-09-23	1.68 (+2.44%)
General meeting for 2025	2025-06-18 10:30	1.37 (-2.14%)
Annual report for 2024	2025-05-21	1.55 (+4.03%)

Show

Entries

Diaceutics PLC Frequently Asked Questions

What is Diaceutics PLC(FRA:7DC)'s stock price today?

The current price of FRA:7DC is €1.64. The 52 week high of FRA:7DC is €2.02 and 52 week low is €1.24.

When is next earnings date of Diaceutics PLC(FRA:7DC)?

The next earnings date of Diaceutics PLC(FRA:7DC) is 2026-09-23 Est..

Does Diaceutics PLC(FRA:7DC) pay dividends? If so, how much?

Diaceutics PLC(FRA:7DC) does not pay dividend.

Press Release

	Subject	Date
	Diaceutics Announces Two Poster Presentations at AMP 2021 Annual Meeting & Expo	2021-09-10
	Two New Experts Join the Diaceutics Advisory Panel	2021-09-08
	Diaceutics to Release Breakthrough Data on COVID-19 Impact on Cancer at 2021 American Society of Clinical Oncology (ASCO) Meeting	2021-06-04
	Diaceutics and LGC SeraCare Partnership Expands Diagnostic Commercialization Solutions Enabled by Global DXRX Platform	2021-05-13
	Diaceutics Appoints Nikita Lynn to Vice President of Finance	2021-03-04
	Canadian Pathology Quality Assurance Leverages Diaceutics' DXRX Platform to Advance NTRK IHC Proficiency Testing	2021-01-18
	Diaceutics Appoints Seasoned Business Leader Deborah Davis as Non-executive Chair	2020-12-22
	Diaceutics and Alva10 partnership to deliver value-based test reimbursement model for US payers, pharma and testing providers via DXRX platform	2020-11-30
	Diaceutics Research Predicts NSCLC US Testing Market to Reach $3.6bn by 2025, but Solution Still Needed to Improve Patient Outcomes	2020-10-05
	Diaceutics Partners With Global EQA Providers to Implement Best-in-class Testing Standards	2020-09-28

10/Page

Articles on Diaceutics PLC

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.